{"id":67648,"date":"2026-06-08T14:48:12","date_gmt":"2026-06-08T06:48:12","guid":{"rendered":"https:\/\/flcube.com\/?p=67648"},"modified":"2026-06-08T14:48:13","modified_gmt":"2026-06-08T06:48:13","slug":"antengene-unveils-atg-207-bispecific-fusion-protein-data-at-eular-2026-novel-%ce%b1cd3xtgf-%ce%b2-molecule-shows-potent-immunomodulatory-activity-in-autoimmune-models","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67648","title":{"rendered":"Antengene Unveils ATG-207 Bispecific Fusion Protein Data at EULAR 2026 \u2013 Novel \u03b1CD3\u00d7TGF-\u03b2 Molecule Shows Potent Immunomodulatory Activity in Autoimmune Models"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Antengene Corporation<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6996:HKG\">HKG: 6996<\/a>) presented compelling preclinical data for <strong>ATG-207<\/strong>, a novel <strong>\u03b1CD3\u00d7TGF-\u03b2 bispecific fusion protein<\/strong>, at the <strong>2026 European Congress of Rheumatology (EULAR 2026)<\/strong>. The molecule demonstrated potent therapeutic activity in multiple autoimmune disease models through its unique mechanism of preferentially binding to <strong>TGF\u03b2RIII<\/strong>, rapidly downregulating T cell receptor expression, and inducing regulatory T cells (Tregs), positioning it as a potential breakthrough therapy for immune-mediated inflammatory disorders.<\/p>\n\n\n\n<h2 id=\"h-molecular-mechanism-amp-differentiation\" class=\"wp-block-heading\">Molecular Mechanism &amp; Differentiation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>ATG-207<\/th><th>Conventional \u03b1CD3-TGF-\u03b2 Control<\/th><\/tr><\/thead><tbody><tr><td><strong>Target Specificity<\/strong><\/td><td>Preferential binding to TGF\u03b2RIII<\/td><td>Non-selective TGF-\u03b2 binding<\/td><\/tr><tr><td><strong>T Cell Modulation<\/strong><\/td><td>Rapid TCR downregulation + Treg induction<\/td><td>Limited Treg differentiation<\/td><\/tr><tr><td><strong>Cytokine Profile<\/strong><\/td><td>Significantly reduced pro-inflammatory cytokines<\/td><td>Higher inflammatory cytokine release<\/td><\/tr><tr><td><strong>Functional Remodeling<\/strong><\/td><td>Extensive proteomic modulation of primary T cells<\/td><td>Minimal functional reprogramming<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-preclinical-efficacy-results\" class=\"wp-block-heading\">Preclinical Efficacy Results<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Experimental Autoimmune Encephalomyelitis (EAE) Model:<\/strong> Significant disease suppression with mouse surrogate molecule<\/li>\n\n\n\n<li><strong>Adoptive T Cell Transfer Colitis Model:<\/strong> Robust therapeutic activity demonstrating broad applicability across autoimmune conditions<\/li>\n\n\n\n<li><strong>Proteomic Analysis:<\/strong> Comprehensive functional remodeling of primary human T cells, indicating durable immunomodulatory effects<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Reduced cytokine release syndrome (CRS) risk compared to conventional bispecific approaches<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-therapeutic-indications-amp-market-opportunity\" class=\"wp-block-heading\">Therapeutic Indications &amp; Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Targets:<\/strong> Multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, and other T cell-mediated autoimmune disorders<\/li>\n\n\n\n<li><strong>Addressable Population:<\/strong> Over 50 million patients globally across target indications with significant unmet medical need<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Differentiated from existing biologics (anti-TNF, IL inhibitors) by targeting root cause through T cell reprogramming<\/li>\n\n\n\n<li><strong>Development Timeline:<\/strong> IND-enabling studies underway; Phase I expected to initiate Q1 2027<\/li>\n\n\n\n<li><strong>Commercial Strategy:<\/strong> Potential for premium pricing in refractory autoimmune populations currently failing standard therapies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-for-antengene\" class=\"wp-block-heading\">Strategic Implications for Antengene<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Diversification:<\/strong> Expands beyond oncology into high-value autoimmune space with novel mechanism<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Demonstrates company&#8217;s bispecific fusion protein technology capabilities<\/li>\n\n\n\n<li><strong>Partnership Potential:<\/strong> Attractive asset for global pharma collaboration given novel mechanism and strong preclinical data<\/li>\n\n\n\n<li><strong>Valuation Impact:<\/strong> Could significantly enhance Antengene&#8217;s market position following clinical validation<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-advantages-amp-innovation\" class=\"wp-block-heading\">Competitive Advantages &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-in-Class Potential:<\/strong> Unique TGF\u03b2RIII-preferential binding mechanism not observed in competing bispecific platforms<\/li>\n\n\n\n<li><strong>Dual Action:<\/strong> Simultaneous TCR downregulation and Treg induction provides comprehensive immune tolerance<\/li>\n\n\n\n<li><strong>Reduced Toxicity:<\/strong> Lower pro-inflammatory cytokine release suggests improved safety profile versus conventional approaches<\/li>\n\n\n\n<li><strong>Broad Applicability:<\/strong> Single molecule potentially effective across multiple autoimmune indications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding preclinical data, development timelines, and commercial potential for ATG-207. Actual results may differ due to clinical trial outcomes, regulatory decisions, competitive developments, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antengene Corporation (HKG: 6996) presented compelling preclinical data for ATG-207, a novel \u03b1CD3\u00d7TGF-\u03b2 bispecific fusion&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[136,65,926],"class_list":["post-67648","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-antengene","tag-auto-immune","tag-hkg-6996"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Antengene Unveils ATG-207 Bispecific Fusion Protein Data at EULAR 2026 \u2013 Novel \u03b1CD3\u00d7TGF-\u03b2 Molecule Shows Potent Immunomodulatory Activity in Autoimmune Models - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Antengene Corporation (HKG: 6996) presented compelling preclinical data for ATG-207, a novel \u03b1CD3\u00d7TGF-\u03b2 bispecific fusion protein, at the 2026 European Congress of Rheumatology (EULAR 2026). The molecule demonstrated potent therapeutic activity in multiple autoimmune disease models through its unique mechanism of preferentially binding to TGF\u03b2RIII, rapidly downregulating T cell receptor expression, and inducing regulatory T cells (Tregs), positioning it as a potential breakthrough therapy for immune-mediated inflammatory disorders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67648\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antengene Unveils ATG-207 Bispecific Fusion Protein Data at EULAR 2026 \u2013 Novel \u03b1CD3\u00d7TGF-\u03b2 Molecule Shows Potent Immunomodulatory Activity in Autoimmune Models\" \/>\n<meta property=\"og:description\" content=\"Antengene Corporation (HKG: 6996) presented compelling preclinical data for ATG-207, a novel \u03b1CD3\u00d7TGF-\u03b2 bispecific fusion protein, at the 2026 European Congress of Rheumatology (EULAR 2026). The molecule demonstrated potent therapeutic activity in multiple autoimmune disease models through its unique mechanism of preferentially binding to TGF\u03b2RIII, rapidly downregulating T cell receptor expression, and inducing regulatory T cells (Tregs), positioning it as a potential breakthrough therapy for immune-mediated inflammatory disorders.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67648\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-08T06:48:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-08T06:48:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67648#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67648\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Antengene Unveils ATG-207 Bispecific Fusion Protein Data at EULAR 2026 \u2013 Novel \u03b1CD3\u00d7TGF-\u03b2 Molecule Shows Potent Immunomodulatory Activity in Autoimmune Models\",\"datePublished\":\"2026-06-08T06:48:12+00:00\",\"dateModified\":\"2026-06-08T06:48:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67648\"},\"wordCount\":416,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Antengene\",\"Auto-immune\",\"HKG: 6996\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67648#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67648\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67648\",\"name\":\"Antengene Unveils ATG-207 Bispecific Fusion Protein Data at EULAR 2026 \u2013 Novel \u03b1CD3\u00d7TGF-\u03b2 Molecule Shows Potent Immunomodulatory Activity in Autoimmune Models - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-08T06:48:12+00:00\",\"dateModified\":\"2026-06-08T06:48:13+00:00\",\"description\":\"Antengene Corporation (HKG: 6996) presented compelling preclinical data for ATG-207, a novel \u03b1CD3\u00d7TGF-\u03b2 bispecific fusion protein, at the 2026 European Congress of Rheumatology (EULAR 2026). The molecule demonstrated potent therapeutic activity in multiple autoimmune disease models through its unique mechanism of preferentially binding to TGF\u03b2RIII, rapidly downregulating T cell receptor expression, and inducing regulatory T cells (Tregs), positioning it as a potential breakthrough therapy for immune-mediated inflammatory disorders.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67648#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67648\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67648#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antengene Unveils ATG-207 Bispecific Fusion Protein Data at EULAR 2026 \u2013 Novel \u03b1CD3\u00d7TGF-\u03b2 Molecule Shows Potent Immunomodulatory Activity in Autoimmune Models\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Antengene Unveils ATG-207 Bispecific Fusion Protein Data at EULAR 2026 \u2013 Novel \u03b1CD3\u00d7TGF-\u03b2 Molecule Shows Potent Immunomodulatory Activity in Autoimmune Models - Insight, China&#039;s Pharmaceutical Industry","description":"Antengene Corporation (HKG: 6996) presented compelling preclinical data for ATG-207, a novel \u03b1CD3\u00d7TGF-\u03b2 bispecific fusion protein, at the 2026 European Congress of Rheumatology (EULAR 2026). The molecule demonstrated potent therapeutic activity in multiple autoimmune disease models through its unique mechanism of preferentially binding to TGF\u03b2RIII, rapidly downregulating T cell receptor expression, and inducing regulatory T cells (Tregs), positioning it as a potential breakthrough therapy for immune-mediated inflammatory disorders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67648","og_locale":"en_US","og_type":"article","og_title":"Antengene Unveils ATG-207 Bispecific Fusion Protein Data at EULAR 2026 \u2013 Novel \u03b1CD3\u00d7TGF-\u03b2 Molecule Shows Potent Immunomodulatory Activity in Autoimmune Models","og_description":"Antengene Corporation (HKG: 6996) presented compelling preclinical data for ATG-207, a novel \u03b1CD3\u00d7TGF-\u03b2 bispecific fusion protein, at the 2026 European Congress of Rheumatology (EULAR 2026). The molecule demonstrated potent therapeutic activity in multiple autoimmune disease models through its unique mechanism of preferentially binding to TGF\u03b2RIII, rapidly downregulating T cell receptor expression, and inducing regulatory T cells (Tregs), positioning it as a potential breakthrough therapy for immune-mediated inflammatory disorders.","og_url":"https:\/\/flcube.com\/?p=67648","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-08T06:48:12+00:00","article_modified_time":"2026-06-08T06:48:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67648#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67648"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Antengene Unveils ATG-207 Bispecific Fusion Protein Data at EULAR 2026 \u2013 Novel \u03b1CD3\u00d7TGF-\u03b2 Molecule Shows Potent Immunomodulatory Activity in Autoimmune Models","datePublished":"2026-06-08T06:48:12+00:00","dateModified":"2026-06-08T06:48:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67648"},"wordCount":416,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Antengene","Auto-immune","HKG: 6996"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67648#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67648","url":"https:\/\/flcube.com\/?p=67648","name":"Antengene Unveils ATG-207 Bispecific Fusion Protein Data at EULAR 2026 \u2013 Novel \u03b1CD3\u00d7TGF-\u03b2 Molecule Shows Potent Immunomodulatory Activity in Autoimmune Models - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-08T06:48:12+00:00","dateModified":"2026-06-08T06:48:13+00:00","description":"Antengene Corporation (HKG: 6996) presented compelling preclinical data for ATG-207, a novel \u03b1CD3\u00d7TGF-\u03b2 bispecific fusion protein, at the 2026 European Congress of Rheumatology (EULAR 2026). The molecule demonstrated potent therapeutic activity in multiple autoimmune disease models through its unique mechanism of preferentially binding to TGF\u03b2RIII, rapidly downregulating T cell receptor expression, and inducing regulatory T cells (Tregs), positioning it as a potential breakthrough therapy for immune-mediated inflammatory disorders.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67648#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67648"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67648#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Antengene Unveils ATG-207 Bispecific Fusion Protein Data at EULAR 2026 \u2013 Novel \u03b1CD3\u00d7TGF-\u03b2 Molecule Shows Potent Immunomodulatory Activity in Autoimmune Models"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67648"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67648\/revisions"}],"predecessor-version":[{"id":67649,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67648\/revisions\/67649"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}